Clinical evaluation of tibric acid (CP 18,524) a new hypolipidemic agent.
D000328:Adult; D000368:Aged; D001565:Benzoates / Q000009:adverse effects / Q000627:therapeutic use; D001835:Body Weight / Q000187:drug effects; D002784:Cholesterol / Q000097:blood; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000150:complications; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use*; D013451:Sulfonic Acids / Q000009:adverse effects / Q000627:therapeutic use; D014280:Triglycerides / Q000097:blood; D014527:Uric Acid / Q000652:urine
D001565:Benzoates; D000960:Hypolipidemic Agents; D008055:Lipids; D010880:Piperidines; D013451:Sulfonic Acids; D014280:Triglycerides; D014527:Uric Acid; D002784:Cholesterol